PD
$17.33
+0.27
(+1.58%)
As of Oct 22, 2026, 2:52 PM EDT · cached
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Jul 21, 2026, the first target we tracked for PD.
Pagerduty Inc (PD) is trading up at $17.33 (+1.58%), as of the latest quote. It is a Russell 2000 constituent in the Information Technology sector.
IPO: April 11, 2019 · $24.00 offering · NYSE · View IPO details →
Analyst price targets on PD
One firm's current price target on Pagerduty Inc: $9 — 48% below the current $17.3. Each is tracked to its date and scored the same way a member's call is.
- Morgan Stanley $9.39 → $9 by Jul 2027 Jul 21, 2026 via Investing.com · Morgan Stanley's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Pagerduty Inc revenue & net income history (FY2018–FY2026)
RevenueNet incomeNet margin (right axis, %)
| FY2018Jan 2018 | FY2019Jan 2019 | FY2020Jan 2020 | FY2021Jan 2021 | FY2022Jan 2022 | FY2023Jan 2023 | FY2024Jan 2024 | FY2025Jan 2025 | FY2026Jan 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $79.6M | $117.8M | $166.4M | $213.6M | $281.4M | $370.8M | $430.7M | $467.5M | $492.5M |
| Growth (year over year) | — | +48.0% | +41.2% | +28.4% | +31.8% | +31.8% | +16.2% | +8.5% | +5.4% |
| Gross profit | $66.9M | $100.6M | $141.8M | $182.9M | $233.0M | $300.4M | $352.9M | $387.8M | $418.4M |
| Gross margin | 84.0% | 85.4% | 85.2% | 85.6% | 82.8% | 81.0% | 81.9% | 83.0% | 84.9% |
| Operating income | −$38.3M | −$42.3M | −$55.6M | −$66.3M | −$101.7M | −$129.4M | −$96.2M | −$59.8M | $5.84M |
| Operating margin | −48.1% | −35.9% | −33.4% | −31.0% | −36.1% | −34.9% | −22.3% | −12.8% | 1.2% |
| Net income | −$38.1M | −$40.7M | −$50.3M | −$68.9M | −$107.5M | −$128.4M | −$75.2M | −$42.7M | $173.4M |
| Net margin | −47.9% | −34.6% | −30.3% | −32.3% | −38.2% | −34.6% | −17.5% | −9.1% | 35.2% |
| EPS (diluted) | −$1.91 | −$1.90 | −$0.77 | −$0.87 | −$1.27 | −$1.45 | −$0.89 | −$0.59 | $1.87 |
| Balance sheet | |||||||||
| Cash and equivalents | $44.0M | $127.9M | $124.0M | $339.2M | $349.8M | $274.0M | $363.0M | $346.5M | $237.4M |
| Total assets | — | $197.2M | $435.4M | $795.4M | $806.4M | $817.9M | $925.3M | $927.3M | $990.5M |
| Total liabilities | — | $93.1M | $127.5M | $428.7M | $539.5M | $575.8M | $746.4M | $779.2M | $719.9M |
| Long-term debt | — | — | — | $303.7M | $300.1M | $296.5M | $489.5M | $484.5M | $420.6M |
| Shareholders' equity | −$56.4M | −$68.9M | $307.9M | $366.7M | $267.0M | $241.0M | $171.6M | $129.8M | $253.6M |
| Cash flow | |||||||||
| Operating cash flow | −$11.8M | −$5.61M | −$173.0K | $10.1M | −$6.02M | $17.0M | $72.0M | $117.9M | $114.9M |
| Capital expenditure | $822.0K | $3.73M | $5.17M | $4.04M | $3.46M | $4.64M | $2.16M | $2.79M | $2.94M |
| Free cash flow | −$12.7M | −$9.34M | −$5.35M | $6.06M | −$9.48M | $12.3M | $69.8M | $115.1M | $111.9M |
| Share buybacks | — | — | — | — | $0 | $0 | $50.0M | $100.1M | $134.9M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY25Oct 2024 | Q4 FY25†Jan 2025 | Q1 FY26Apr 2025 | Q2 FY26Jul 2025 | Q3 FY26Oct 2025 | Q4 FY26†Jan 2026 | Q1 FY27Apr 2026 | Q2 FY27Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $118.9M | $121.4M | $119.8M | $123.4M | $124.5M | $124.8M | $121.0M | $124.4M |
| Growth (year over year) | +9.4% | +9.3% | +7.8% | +6.4% | +4.7% | +2.7% | +1.0% | +0.8% |
| Gross profit | $98.7M | $101.5M | $100.6M | $104.4M | $106.2M | $107.2M | $101.9M | $104.4M |
| Gross margin | 83.0% | 83.6% | 84.0% | 84.6% | 85.3% | 85.9% | 84.3% | 83.9% |
| Operating income | −$10.3M | −$11.7M | −$10.3M | $3.57M | $8.08M | $4.52M | $9.18M | $10.2M |
| Operating margin | −8.7% | −9.6% | −8.6% | 2.9% | 6.5% | 3.6% | 7.6% | 8.2% |
| Net income | −$5.92M | −$8.76M | −$7.16M | $9.57M | $161.6M | $9.37M | $5.28M | $7.79M |
| Net margin | −5.0% | −7.2% | −6.0% | 7.8% | 129.7% | 7.5% | 4.4% | 6.3% |
| EPS (diluted) | −$0.07 | −$0.12 | −$0.07 | $0.10 | $1.69 | $0.15 | $0.13 | $0.06 |
| Balance sheet | ||||||||
| Cash and equivalents | $326.4M | $346.5M | $371.8M | $339.7M | $324.3M | $237.4M | $208.9M | $233.7M |
| Total assets | $866.8M | $927.3M | $926.8M | $891.5M | $1.03B | $990.5M | $936.6M | $958.3M |
| Total liabilities | $738.7M | $779.2M | $763.8M | $693.9M | $688.4M | $719.9M | $708.1M | $711.4M |
| Long-term debt | — | $484.5M | — | — | — | $420.6M | — | — |
| Shareholders' equity | $111.6M | $129.8M | $145.7M | $180.7M | $320.5M | $253.6M | $216.5M | $232.0M |
| Cash flow | ||||||||
| Operating cash flow | $22.1M | $31.4M | $30.7M | $34.0M | $24.8M | $25.4M | $44.3M | $36.9M |
| Capital expenditure | $552.0K | $1.15M | $441.0K | $874.0K | $743.0K | $883.0K | $965.0K | $2.23M |
| Free cash flow | $21.5M | $30.3M | $30.2M | $33.1M | $24.1M | $24.5M | $43.3M | $34.7M |
| Share buybacks | $70.3M | $2.58M | $0 | $0 | $36.1M | $98.8M | $65.5M | $7.48M |
From Pagerduty Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in January. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Pagerduty Inc
- Headquarters
- San Francisco, California From SEC filings, Oct 2026
Recent News (7)
-
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in Previously Untreated Disease Expansion Stage to Compare Opamtistomig Plus Chemotherapy He…
-
PagerDuty executive chair Jennifer Tejada sells $986,987 in stock
PagerDuty executive chair Jennifer Tejada sells $986,987 in stock
-
PagerDuty executive chair Jennifer Tejada sells $1.6 million in shares
PagerDuty executive chair Jennifer Tejada sells $1.6 million in shares
-
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Enrolls First Patient in Phase Ib/II Combination Trial in Metastatic Colorectal Cancer Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer Extending the Company's Immunologically Cold Tumor Strategy into Colorectal Cancer
-
-
First Patient Dosed in Phase III Perioperative Study of Cadonilimab (PD-1/CTLA-4) in Colon Cancer HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evalua…
-
Morgan Stanley downgrades PagerDuty stock rating on AI threats Morgan Stanley downgrades PagerDuty stock rating on AI threats
More Information Technology stocks
- ALAB Astera Labs
- ARM Arm Holdings
- ASML ASML Holding
- MRVL Marvell Technology
- TWLO Twilio
- AAPL Apple Inc.
- ACN Accenture
- ADBE Adobe Inc.